Concepedia
Statistics
Publications
16
Citations
1.5K
H-Index
13
Active since
2006
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)
Dana-Farber Cancer Institute
Hackensack University Medical Center
Decision Sciences (United States)
Princess Margaret Cancer Centre
Linda Sun is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and pharmacology.
Publications per year
2006–2023
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen Sandhu, William R. Schelman, George Wilding et al. · The Lancet Oncology · 2013 · 558 citations
Medicine, Oncology, Pharmacology +12
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Α. Dimopoulos, David S. Siegel, Sagar Lonial et al. · The Lancet Oncology · 2013 · 227 citations
Medicine, Pharmacology, Pharmacotherapy +14
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul G. Richardson, Constantine Mitsiades, Kathleen Colson et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 191 citations
Pharmacy, Pharmacology, Pharmacotherapy +15
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Michael Crump, Bertrand Coiffier, Eric D. Jacobsen et al. · Annals of Oncology · 2008 · 180 citations · Full text
Medicine, Hematology, Oncology +14
A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer
Eric H. Rubin, Nancy Agrawal, Evan Friedman et al. · Clinical Cancer Research · 2006 · 113 citations · Full text
Pharmacy, Oncology, Pharmacology +17
1–5 of 16